Calinas Filipe, Cardoso Hélder, Carvalhana Sofia, Ferreira José, Gonçalves Cristina, Magalhães Marina, Miranda Helena Pessegueiro, Presa José, Rolanda Carla, Santos Arsénio, Santos Rui M
Centro de Responsabilidade Integrado de Gastrenterologia, Unidade Local de Saúde de São José, Lisbon, Portugal.
Centro Clínico Académico de Lisboa, Lisbon, Portugal.
GE Port J Gastroenterol. 2024 Nov 5;32(2):78-94. doi: 10.1159/000541208. eCollection 2025 Apr.
Wilson disease (WD) is a genetic disorder of copper metabolism caused by mutations in the ATP7B gene resulting in toxic copper accumulation in several organs. WD can manifest as liver disease, a progressive neurological disorder, a psychiatric illness, or a combination of these. Other clinical manifestations can also occur. Diagnosis is challenging and typically requires a range of biochemical tests, imaging, genetic testing for ATP7B, and/or liver biopsy. WD is treatable with chelating agents, such as d-penicillamine and trientine, and/or zinc salts alongside with dietary copper restriction. Liver transplantation may be indicated in WD patients with severe hepatic disease, and cautiously considered in patients with neurological WD. Treatment success highly depends on patient adherence and treatment persistence. Therefore, effective interventions for improving patient adherence and close monitoring are key for preventing WD progression. In Portugal, there are no reference centers for WD, and patients are dispersed across numerous medical specialists. This review aimed to summarize the most recent and relevant information for the diagnosis, treatment, and monitoring of WD in Portugal, as well as possible interventions for stimulating adherence to treatment.
威尔逊病(WD)是一种铜代谢的遗传性疾病,由ATP7B基因突变引起,导致多个器官中有毒铜的积累。WD可表现为肝病、进行性神经障碍、精神疾病或这些情况的组合。也可能出现其他临床表现。诊断具有挑战性,通常需要一系列生化检查、影像学检查、ATP7B基因检测和/或肝活检。WD可用螯合剂(如d-青霉胺和曲恩汀)和/或锌盐治疗,同时限制饮食中的铜摄入。对于患有严重肝病的WD患者,可能需要进行肝移植,对于患有神经型WD的患者则需谨慎考虑。治疗的成功高度依赖于患者的依从性和治疗的持续性。因此,改善患者依从性的有效干预措施和密切监测是预防WD进展的关键。在葡萄牙,没有WD的参考中心,患者分散在众多医学专家处。本综述旨在总结葡萄牙关于WD诊断、治疗和监测的最新相关信息,以及促进治疗依从性的可能干预措施。